O-PCE Stats & Data

Harm‑reduction rationale and key guidance (with sources): 1) Mislabeling/adulteration: O‑PCE has been repeatedly sold as “ketamine,” creating overdose risk due to higher potency and longer duration; Swiss drug‑checking issued a 2025 alert for 2‑Oxo‑PCE sold as ketamine and warned it may be 3–4× stronger with longer effects. Always use a trusted drug‑checking service before use. 2) Acute toxicity profile: a 2017 outbreak (n=56) found predominant impaired consciousness (84%), confusion (60%), hypertension (80%), tachycardia (40%), and convulsions (16%) with confirmed O‑PCE as sole agent in many cases; management was supportive. Avoid if you have uncontrolled cardiovascular disease or seizure history. 3) Duration can outlast ketamine: community HR sources report 2–5 h (IN) and 3–6+ h (oral) with after‑effects up to 1–2 days; some services warn 6–10 h at higher doses. Plan set/setting, avoid driving/operating machinery for the rest of the day, and keep a sober sitter for higher doses. 4) Redosing risks: slow come‑up and long plateaus make stacking common; wait at least 60–120 min (IN) or 2–3 h (oral) before considering any additional dosing to avoid unexpectedly deep dissociation or holes. 5) Depressant combinations (alcohol, benzos, opioids, GHB) increase sedation, confusion and aspiration risk; avoid these mixes. General combo guidance flags dissociative+depressant as risky. Carry naloxone if opioids may be present in your supply. 6) Stimulant and polysubstance use: stimulants may exacerbate O‑PCE‑related hypertension, anxiety, and mania‑like states; polysubstance cases were common in outbreaks. Titrate especially cautiously if any stimulant is onboard. 7) Bladder/urinary risk likely extends to this class: ketamine cystitis is well‑documented and can progress to severe LUTS and renal complications; while direct O‑PCE data are limited, class‑based caution (limit frequency, hydrate, seek care early if urinary symptoms emerge) is prudent. Avoid if you currently have a UTI. 8) Nasal harm reduction: finely crush, use your own straw, and rinse with sterile water/saline before and after to reduce mucosal damage; repeated snorting can injure septum. Consider oral dosing to reduce local damage. 9) Tolerance and compulsive use: arylcyclohexylamines can produce rapid tolerance (days) with partial reset over 1–2 weeks; spacing sessions helps reduce escalation and dependence risk. 10) Market variability and isomer confusion: fluorinated analogs (e.g., “FXE”) have been widely misidentified in the unregulated market; this underscores the need for professional analysis rather than assuming identity from vendor labels.